Revance's acquisition by Crown Laboratories completed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2025
0mins
Crown Laboratories Acquisition: Crown Laboratories has successfully completed its acquisition of Revance Therapeutics, following a tender offer that expired on February 4, with approximately 82% of shares validly tendered.
Delisting and Deregistration: As a result of the acquisition, Revance's common stock will be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
